AUG 15, 2018 12:00 AM PDT

Cancer Control Headway in The Last 20 Years

WRITTEN BY: Mauri Brueggeman

Cancer, as a disease, is believed to have been around since 1600 B.C. where human bone cancers were found in Egyptian mummies and were documented in very early manuscripts from that time.  The term “cancer” is from the Greek word karkinos which is related to a crab; the Greek saw cancer like a crab where it grabbed hold and would not let go as well as having multiple arms to spread out within an animal.  Carcinomas were originally described by Hippocrates around 400 B.C.  This brief history is provided simply to illustrate that this is a very old disease, although it seems like we didn’t start noticing it until well into the 1900s. 

While the disease itself may be old, the data collected is less so.  Cancer control data has been documented since the early 1900s where providers of that time looked to detect cancer early via physical signs or symptoms and proceeded with surgical interventions.  Cancer control, as an academic science field was not recognized until the mid-twentieth century when more consistent early screening tests became more widely accepted.  Cancer control, as a subspecialty, is focused on providing education and information to the public and clinical providers to reduce the cancer burden on society.  Their practices include prevention strategies, early detection, and treatment interventions. 

The American Cancer Society is providing current literature on their analysis of the National Center for Health Statistics data on cancer mortality trends and concerns for the future and the first article published in CA: A Cancer Journal for Clinicians outlines where we have come in thwarting this very old disease. 

The three metrics often used in analyses of cancer control progress are incidence rates, survival rates, and death rates.  The group that authored the aforementioned article chose to evaluate our outcomes based on mortality rates because these are less affected by the multitude of interventions that have been developed in the last two to three decades.  In analyzing data from 1930 to 2015, the peak mortality rate occurred in 1991 where 215 individuals out of 100,000 were dying of cancer.  Those numbers have declined dramatically at a rate of 26% in the past 24 years overall.  The four big cancers that account for nearly half of all cancer deaths, namely lung, colorectal, breast, and prostate, have decreased their mortality rates which collectively lowered the overall rate in dramatic fashion (36% decline for these 4 cancers from 1991 to 2015).  The reasoning for this decline includes the work being done on cancer prevention including significant decreases in smoking and the recognition and removal of pre-cancerous colorectal or cervical lesions, thus affecting the incidence rates.  In fact, the increase and enhancement of screening techniques may have increased the incidence rates, but the mortality rate declined because cancers are being detected and treated earlier, leading to higher remission rates.  Lastly, these numbers are attributed to improvements in surgical interventions leading to fewer surgical complications and death as well as better therapeutic approaches and management of those approaches. 

There are still opportunities to improve these numbers in the next 20 years, however.  Lung cancer remains the leading cause of cancer deaths and while there is a decline in smoking and cancer related deaths since the 55% mortality rate peak in 1991 for this particular disease, there are still areas or populations that maintain smoking habits which will continue to affect cancer rates.  Additional opportunities with cervical cancer lie in education and awareness that in the United States in 2016, less than 1 in 2 females utilized the human papillomavirus vaccine which has been proven to severely minimize the potential for cervical cancer development.  This one change could eliminate cervical cancer which is still considered a major cause of morbidity and mortality.  In addition, there are opportunities to better educate on the differences in prevalence and cancer rates based on race and ethnicity of individuals.  Lastly, there are continued opportunities to mitigate health disparities brought about by differences in access to health care.  These pieces are critical to continuing to effect positive change on cancer death rates, driving innovative and effective therapies, and reducing the cancer burden for the public.

Source: CA: A Cancer Journal for Clinicians,

About the Author
Master's (MA/MS/Other)
Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
OCT 04, 2022
Cardiology
Brisk Walking Reduces Risk of Heart Disease, Cancer, and More
Brisk Walking Reduces Risk of Heart Disease, Cancer, and More
Getting your steps in at a brisker pace reduces the risk of cancer, heart disease, dementia, and premature death.
DEC 05, 2022
Health & Medicine
Favorable and Unfavorable Prognostic Genes in Human Cancers
Favorable and Unfavorable Prognostic Genes in Human Cancers
Favorable and Unfavorable Prognostic Genes in Human Cancers Cancer is a leading cause of death worldwide, so there is an ...
NOV 29, 2022
Cell & Molecular Biology
How a Master Regulator May be Working to Protect Cancer
How a Master Regulator May be Working to Protect Cancer
Scientists have now discovered yet another way that MYC proteins can promote cancer. MYC has been called a master regula ...
DEC 10, 2022
Cell & Molecular Biology
Using AI to Build a Better Immunotherapy
Using AI to Build a Better Immunotherapy
T cells that are used in immunotherapy have to be programmed to efficiently destroy cancer cells. Researchers have now u ...
DEC 16, 2022
Drug Discovery & Development
The Age of mRNA Cancer Vaccines Starts with Melanoma
The Age of mRNA Cancer Vaccines Starts with Melanoma
Earlier this week, pharmaceuticals Merck and Moderna announced “the first demonstration of efficacy” for an ...
JAN 05, 2023
Cancer
A Triple Immunotherapy Regimen for Pancreatic Cancer
A Triple Immunotherapy Regimen for Pancreatic Cancer
Immunotherapy, including immune checkpoint inhibitors (ICIs), has changed the landscape of cancer treatment in the last ...
Loading Comments...